Linda G Strause, PH.D.
- Title
- President @
- Company
- PSLY
Dr. Strause brings 30+ years of expertise in global clinical operations and clinical development, with an emphasis in oncology, critical care, and ethical considerations for subjects with life-threatening diseases, to the emerging market of psilocybin and psychedelics. Dr. Strause has held executive management positions at biotechnology companies, site management and healthcare research organizations, and at a global CRO. In addition she has been a Professor of Human Nutrition at the University of California, San Diego for over 30 years. In January 2022 Dr. Strause joined Ei.Ventures/Psilly as President. She is responsible for overseeing all clinical development programs with a specific focus on psychedelics. In addition, she has responsibilities to ensure that operations are conducted efficiently and effectively across all of Ei.Ventures/Psilly endeavors including, but not limited to, botanical health products, technology applications, and web3 performance. Ei (Emotional Intelligence) Ventures, is committed to the advancement of a safe, clean, and healthful world through the wisdom of plants.
Past Speaking Events
- Psilly - Solving America's Mental Health Crisishosted by PSLYMarch 17, 20221:00 PM - 2:00 PMWebcast
About PSLY
More people than ever are struggling with mental health. As a society, we don’t currently have adequate mental health treatment that targets the root problem without hefty costs (reliance on daily medication, side effects, potential substance abuse). Big Pharma has failed to address the problem and the world wants a different solution.
Psilocybin and functional mushrooms allow us to rewire our neural pathways and naturally address what we typically try to control via medication. Psilly, brought to you by E.I. Ventures, is changing the narrative around psychedelic therapy so that plant-powered mushrooms can move through FDA trials and provide people a safer and more efficient path to self-improvement.
Psilly provides a path to what’s growing all around us: a “gold standard” of plant-powered, psychedelic therapy. Rather than compete over ownership of a natural compound, Psilly offers a delivery system, therapeutic framework, educational platform, and community that will ensure that people experience the value that psychedelic mushrooms have to offer for as accessible a cost as possible - $1 per dose.
We are focused on three key areas in order to scale psychedelic therapy and mental health and wellness options to the millions currently suffering:
1. Botanical pharmaceutical ingredients
2. Drug delivery mechanisms
3. Web3 psychedelic therapy and technology
Invest in Psilly, brought to you by E.I. Ventures, to bring 100% plant-based therapies through FDA trials to help 1 billion people for $1 each.
Learn more at invest.ei.ventures
We started our journey over 12 years ago in Los Angeles, bringing healing modalities to a growing community of individuals curious about alternative paths to health and wellness. Then came the island of Maui, Hawaii, where we connected with farmers, chemists, and iconic leaders of psychedelic medicine to explore the power of the plant and natural therapies that unlock the mind and heal the soul. Psilly, a continuation of Orthogonal Thinker and E.I. Ventures's mission of conscious, sustainable investing and community building, was born in 2021.
Our team consists of experts, teachers, and healers from across innovative corners of psychedelic medicine, cannabis, CBD, academia, and physical healing spaces. Working and living across Miami, Maui, and Northern California, we all share a common respect for natural medicine and what's possible when you reimagine the strategy of pharmaceuticals to present people with a new path to self-improvement.